The @ACRheum RA outcome measures toolkit has all the relevant tools for measuring outcomes in rheumatoid arthritis (and exactly how to do it). https://t.co/GZ7tZ6fNMK Great for all US rheumatologists, but also very handy for all of us globally #ACR24 16S30 @JYazdany @RheumNow https://t.co/MSHA353MKR

• Rheumatoid Arthritis (RA) Measures Toolkit
• https://x.com/drdavidliew/status/1858129460194898378/photo/1

RheumNow Day 1 Recap: ACR Convergence 2024 Highlights https://t.co/xjCMpzXhTE

• Dr. John Cush

Race of b/tsDMARDs in RA, the “JAK-pot” study. JAKi and TNFi with more rapid early improvement in CDIA, HAQ, and pain compared to ABA or IL-6 inhibitors…..although effects blunted after adjusting for patient and RA characteristics #ACR24 @RheumNow ABST#0501 https://t.co/8M4wX3LAbW

• https://x.com/JihaRheum/status/1857895166117384500/photo/1

How does #cardiovascular risk vary with #ACPA & #biologics in #RA? ⬆️BMI assoc with ⬆️MACE risk in ACPA+ pts In ACPA- pts, BMI inversely assoc with MACE risk among pts on biologics Further evidence to consider ACPA, BMI & MACE as part of RA management Ab0870 #ACR24 @RheumNow https://t.co/UkkC146DWS

• https://x.com/DrMiniDey/status/1857893908073820672/photo/1

Cross-sectional study finds metabolic dysregulation in RA-ILD is indicative of poor prognosis- FGF-21 assoc w. poor survival. Another link btwn CV risk factors, metabolic syndrome & RA? Should we be doing more to manage metabolic risk factors in RA-ILD? Ab0803 #ACR24 @RheumNow

Not just the presence but higher levels of biomarkers predict RA-ILD progression. #ACR24 @RheumNow ABST#0804 https://t.co/5jhBjXDUeY

• https://x.com/JihaRheum/status/1857886358020223371/photo/1

Medication-assisted weight loss has boomed in recent yrs. How does weight loss affect disease activity & PROs in RMDs? ≥5% weight loss, after taking a med, led to better disease activity & QoL Data may inform RCTs to explore effect of these meds in RMDs Ab0845 #ACR24 @RheumNow